¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

2024³â Á¦39ȸ ´ëÇÑ°£ÇÐȸ Ãá°è Single Topic Symposium : 2024-03-16

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 

2024³â Á¦39ȸ ´ëÇÑ°£ÇÐȸ Ãá°è Single Topic Symposium : 2024-03-16
±³À°ÀÏÀÚ : 2024-03-16
±³À°Àå¼Ò : ±¤ÁÖ ±è´ëÁß ÄÁº¥¼Ç ¼¾ÅÍ, ÄÁº¥¼ÇȦ (4Ãþ)

±³À°ÁÖÁ¦ : 2024³â Á¦39ȸ ´ëÇÑ°£ÇÐȸ Ãá°è Single Topic Symposium

ÁÖÃÖ±â°ü : ´ëÇÑ°£ÇÐȸ
´ã´çÀÚ : ´ëÇÑ°£ÇÐȸ
¿¬¶ôó : 02-703-0051  

À̸ÞÀÏ : kasl@kams.or.kr

±³À°Á¾·ù : ³»°ú

Âü¼®¿¹»óÀÎ : 200¸í
Èñ¸ÁÆòÁ¡ : 4Á¡

Áö¿ª : ±¤ÁÖ±¤¿ª½Ã
±³À°½Ã°£ : 5 ½Ã°£ 0ºÐ

¼¼ºÎ¼ö°­·á : 50,000¿ø  

ºñ°í "»çÀüµî·Ï ȸ¿ø, ÀüÀÓÀÇ, Àü°øÀÇ 30,000¿ø ºñȸ¿ø, ¿Â¶óÀΠȸ¿ø 40,000¿ø

ÇöÀåµî·Ï ȸ¿ø, ÀüÀÓÀÇ, Àü°øÀÇ 40,000¿ø ºñȸ¿ø, ¿Â¶óÀΠȸ¿ø 50,000¿ø 

¿Â¶óÀÎ Âü¿© ¹«·á"  


±¸ºÐ ¿ùÀÏ °­ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ

±³À°½Ã°£ 03¿ù 16ÀÏ ±¤ÁÖ ±è´ëÁß ÄÁº¥¼Ç ¼¾ÅÍ, ÄÁº¥¼ÇȦ (4Ãþ) 10:10~10:30 Mechanisms of Metabolic Dysfunction and Disease Consequences of MASLD(NAFLD) ¼Õ¿ø(¼º±Õ°üÀÇ´ë)

±³À°½Ã°£ 03¿ù 16ÀÏ ±¤ÁÖ ±è´ëÁß ÄÁº¥¼Ç ¼¾ÅÍ, ÄÁº¥¼ÇȦ (4Ãþ) 10:30~10:50 Impact of Metabolic Risk Factors on Prognosis in Patients with Chronic Viral Hepatitis À±ÀçÇö(Àü³²ÀÇ´ë)

±³À°½Ã°£ 03¿ù 16ÀÏ ±¤ÁÖ ±è´ëÁß ÄÁº¥¼Ç ¼¾ÅÍ, ÄÁº¥¼ÇȦ (4Ãþ) 10:50~11:10 Guidance for Surveillance and Diagnosis of HCC in Patients with MASLD(NAFLD) °û±Ý¿¬(¼º±Õ°üÀÇ´ë)

±³À°½Ã°£ 03¿ù 16ÀÏ ±¤ÁÖ ±è´ëÁß ÄÁº¥¼Ç ¼¾ÅÍ, ÄÁº¥¼ÇȦ (4Ãþ) 11:10~11:30 Recent Advances in Lean MASLD(NAFLD) and Sarcopenia À¯Á¤È¯(ÀÎÇÏÀÇ´ë)

Åä·Ð 03¿ù 16ÀÏ ±¤ÁÖ ±è´ëÁß ÄÁº¥¼Ç ¼¾ÅÍ, ÄÁº¥¼ÇȦ (4Ãþ) 11:30~11:50 Discussion ( )

±³À°½Ã°£ 03¿ù 16ÀÏ ±¤ÁÖ ±è´ëÁß ÄÁº¥¼Ç ¼¾ÅÍ, ÄÁº¥¼ÇȦ (4Ãþ) 12:50~13:10 Lifestyle Modifications in Obese and Lean Patients with MASLD(NAFLD): Different Way? ±èÁÖ¿µ(¹ÙÀÌ¿À´ºÆ®¸®¿Â)

±³À°½Ã°£ 03¿ù 16ÀÏ ±¤ÁÖ ±è´ëÁß ÄÁº¥¼Ç ¼¾ÅÍ, ÄÁº¥¼ÇȦ (4Ãþ) 13:10~13:30 Endocrinologic Practice for Diabetes, Osteoporosis, and Obesity in Chronic Liver Disease ±èÁøÈ­(Á¶¼±ÀÇ´ë)

±³À°½Ã°£ 03¿ù 16ÀÏ ±¤ÁÖ ±è´ëÁß ÄÁº¥¼Ç ¼¾ÅÍ, ÄÁº¥¼ÇȦ (4Ãþ) 13:30~13:50 Cardiovascular Practice for Dyslipidemia, Hypertension, and Atherosclerosis in Chronic Liver Disease Á¶°æÈÆ(Àü³²ÀÇ´ë)

±³À°½Ã°£ 03¿ù 16ÀÏ ±¤ÁÖ ±è´ëÁß ÄÁº¥¼Ç ¼¾ÅÍ, ÄÁº¥¼ÇȦ (4Ãþ) 13:50~14:10 Specific Issues and Concerns in the Management of MASLD(NAFLD)-Related HCC Á¶ÁÖ¿¬(Á¶¼±ÀÇ´ë)

Åä·Ð 03¿ù 16ÀÏ ±¤ÁÖ ±è´ëÁß ÄÁº¥¼Ç ¼¾ÅÍ, ÄÁº¥¼ÇȦ (4Ãþ) 14:10~14:30 Discussion ( )

±³À°½Ã°£ 03¿ù 16ÀÏ ±¤ÁÖ ±è´ëÁß ÄÁº¥¼Ç ¼¾ÅÍ, ÄÁº¥¼ÇȦ (4Ãþ) 14:50~15:10 Introduction and Implications of New NAFLD Nomenclatures: MAFLD vs. MASLD À±¾ÆÀϸ°(ÇѾçÀÇ´ë)

±³À°½Ã°£ 03¿ù 16ÀÏ ±¤ÁÖ ±è´ëÁß ÄÁº¥¼Ç ¼¾ÅÍ, ÄÁº¥¼ÇȦ (4Ãþ) 15:10~15:30 Noninvasive Evaluation of MASLD(NAFLD) and Liver Fibrosis: Clinically Applicable? ÀÌâÈÆ(ÀüºÏÀÇ´ë)

±³À°½Ã°£ 03¿ù 16ÀÏ ±¤ÁÖ ±è´ëÁß ÄÁº¥¼Ç ¼¾ÅÍ, ÄÁº¥¼ÇȦ (4Ãþ) 15:30~15:50 Molecular Basis and Mechanisms of Progression of MASH(NASH) ÇÑ¿ëÇö(°­¿ø¾à´ë)

±³À°½Ã°£ 03¿ù 16ÀÏ ±¤ÁÖ ±è´ëÁß ÄÁº¥¼Ç ¼¾ÅÍ, ÄÁº¥¼ÇȦ (4Ãþ) 15:50~16:10 Current and Emerging Pharmacological Options for MASH(NASH) and Obesity À̽¿ø(°¡Å縯ÀÇ´ë)

Åä·Ð 03¿ù 16ÀÏ 16:10~16:30 Discussion ( )

 

ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" 2024³â Á¦39ȸ ´ëÇÑ°£ÇÐȸ Ãá°è Single Topic Symposium : 2024-03-16""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ¼øõÇâ´ëÇб³ºÎõº´¿ø NeuroAngio Hub °³¼Ò±â³ä ±¹Á¦½ÉÆ÷Áö¾ö : 2024-03-16
´ÙÀ½±Û Á¦22ȸ ´ëÇÑ´ç´¢º´ÇÐȸ Ãá°è ½ÉÆ÷Áö¾ö : 2024-03-16
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
21090 ¼­¿ï 2024³â ´ëÇѼö¸é¿¬±¸ÇÐȸ Á¤±â Çмú´ëȸ DAY 2 : 2024-07-07 0 7 2024-06-19
21089 ¼­¿ï ´ëÇÑÇǺΰúÇÐȸ 2024³â Á¦4ȸ Àü¹®ÀÇ ¿¬¼ö°­Á : 2024-07-07 0 13 2024-06-19
21088 ºÎ»ê 2024 ´ëÇѺñ¸¸ÇÐȸ ºÎ¿ï°æÁöȸ Ãá°è¿¬¼ö°­Á : 2024-07-06 0 35 2024-06-18
21087 ¼­¿ï 2024 °­ºÏ»ï¼ºº´¿ø ¼ÒÈ­±â ½ÉÆ÷Áö¾ö : 2024-07-06 0 20 2024-06-18
21086 ´ëÀü Çѱ¹È£½ºÇǽº¡¤¿ÏÈ­ÀÇ·áÇÐȸ 2024³â ÇÏ°èÇмú´ëȸ : 2024-07-06 0 12 2024-06-18
21085 ¼­¿ï ¼­¿ï´ëÇб³º´¿ø 2024 Á¶¿µÁ¦ ¾ÈÀü°ü¸® ½ÉÆ÷Áö¾ö : 2024-07-06 0 17 2024-06-18
21084 ¼­¿ï Á¦22ȸ ¼­¿ï½Ã ³²¼­ 7°³±¸ ÀÇ»çȸ ÇÕµ¿ Çмú´ëȸ : 2024-07-06 0 7 2024-06-18
21083 ±¤ÁÖ ±¤ÁÖÀü³²³»°úÀÇ»çȸ Á¦6ȸ ÃÊÀ½ÆÄ ÇÚÁî¿Â ¿öÅ©¼ó : 2024-07-06 0 9 2024-06-18
21082 ¼­¿ï 2024 ´ëÇѹ®¸Æ¾ÐÇ×ÁøÁõ¿¬±¸È¸ ½ÉÆ÷Áö¾ö : 2024-07-06 0 7 2024-06-18
21081 °­¿ø 2024³â ´ëÇѳ»°úÇÐȸ °­¿øÁöȸ ÇÏ°è ¿¬¼ö°­Á : 2024-07-06 0 7 2024-06-18
21080 °æ±â 2024³â °í´ë¾È»ê ³»°ú °³¿øÀÇ ¿¬¼ö°­Á : 2024-07-06 0 7 2024-06-18
21079 ¼­¿ï 2024 È£Èí±â°¨¿°º´ ¿¬±¸È¸ ½ÉÆ÷Áö¾ö : 2024-07-06 0 9 2024-06-18
21078 ºÎ»ê ´ëÇÑÀ̺ñÀÎÈÄ°úÀÇ»çȸ 2024 Áöȸ&ÁöºÎ ½ÉÆ÷Áö¾ö-ºÎ¿ï°æ : 2024-07-06 0 7 2024-06-18
21077 ¼­¿ï ´ëÇÑÅ»ÀåÇÐȸ 18th Congress of the KHS & 2024 International Symposium(2ÀÏÂ÷) : 2024-07-06 0 16 2024-06-18
21076 ¼­¿ï ´ëÇÑ¿Ü°úÃÊÀ½ÆÄÇÐȸ 2024 Breast Biopsy Symposium : 2024-07-06 0 14 2024-06-18
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷